Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

The health landscape sees pivots as companies adjust strategies: Bristol Myers and Pfizer offer discounts on Eliquis, Newcastle University's IVF technique prevents genetic diseases, and Juul's ...

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer discussed what bank industry executives were saying about ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Bristol Myers Squibb (NYSE:BMY) announced on Friday that its anemia therapy, Reblozyl, developed with Merck (NYSE:MRK), did not meet the main goal in a Phase 3 trial for certain adults with a rare ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

These four dividend stocks are ideal choices for growth and income investors seeking reliable passive income with some growth potential.

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Health-care companies fell after a lackluster round of earnings. Shares of medical-device maker Abbott Labs shares tumbled by more than 8% after it trimmed and narrowed its 2025 growth projections ...